8-K: Veru Inc. Announces Full Enrollment in Phase 2b Enobosarm Obesity Trial and Reports Q3 Fiscal 2024 Results

Veru Inc. has completed enrollment for its Phase 2b clinical trial of enobosarm for obesity and reported its third quarter fiscal 2024 financial results.

Summary

• Veru Inc. announced the full enrollment of over 150 patients in its Phase 2b QUALITY clinical trial for enobosarm, a drug aimed at preserving muscle mass during weight loss with GLP-1 receptor agonists.
• Topline data for the primary endpoint, lean body mass, is expected in January 2025.
• The company also reported its fiscal 2024 third quarter results, with net revenues increasing to $4.0 million from $3.3 million year-over-year.
• Gross profit increased to $1.3 million from $1.2 million, while research and development expenses decreased to $4.9 million from $8.8 million.
• The operating loss decreased to $10.9 million from $13.7 million, and the net loss was $11.0 million, or $0.07 per share, compared to $12.5 million, or $0.14 per share, in the prior year.
• Year-to-date, net revenues decreased to $10.2 million from $12.4 million, primarily due to a $3.9 million loss from The Pill Club bankruptcy in the prior year.
• The company's cash and cash equivalents were $29.2 million as of June 30, 2024, compared to $9.6 million as of September 30, 2023.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the full enrollment of the clinical trial and improved financial metrics. However, there are still losses and risks associated with the company's operations, which temper the overall sentiment.

Positives

• Full enrollment was achieved in the Phase 2b QUALITY clinical trial, indicating strong progress in the study.
• The company has presented data at multiple scientific conferences, increasing visibility for enobosarm.
• Third quarter net revenues and gross profit increased year-over-year.
• Research and development and selling, general and administrative expenses decreased significantly year-over-year.
• The company's cash position has improved significantly, providing more financial stability.

Negatives

• Year-to-date net revenues decreased due to a $3.9 million loss from The Pill Club bankruptcy.
• The company continues to report an operating loss and net loss, although these have decreased compared to the previous year.
• The company is reliant on external funding for further development of sabizabulin for viral-induced ARDS.

Risks

• The success of the enobosarm clinical trial is not guaranteed, and results may not meet expectations.
• The company's ability to fund planned clinical development and operations is subject to risks.
• There are risks associated with the commercial success of the company's products, including competition and market acceptance.
• The company's reliance on international partners and government spending could impact revenue.
• The company faces risks related to production capacity, supply constraints, and potential litigation.

Future Outlook

The company anticipates topline data from the Phase 2b QUALITY clinical trial in January 2025 and topline results from the extension study in the second calendar quarter of 2025. The company is focused on developing novel medicines for metabolic diseases, oncology, and ARDS.

Management Comments

• Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc., stated that they are very pleased to have reached full enrollment in the Phase 2b QUALITY clinical trial.
• Dr. Steiner also noted the substantial unmet medical need for a drug that can effectively preserve muscle mass while enhancing fat loss in patients using GLP-1 drugs.

Industry Context

The announcement is relevant to the growing interest in treatments for obesity and the potential for drugs that can preserve muscle mass while promoting weight loss, particularly in the context of GLP-1 receptor agonist use. The company is positioning enobosarm as a solution to the muscle loss issues associated with GLP-1 drugs.

Comparison to Industry Standards

• The Phase 2b trial is focused on a specific niche of patients using GLP-1 drugs, which is a growing area of interest in the pharmaceutical industry.
• Companies like Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro) are leading the GLP-1 market, but there is a need for therapies that address muscle loss, which Veru is targeting with enobosarm.
• The trial's focus on lean body mass as a primary endpoint is aligned with the industry's increasing recognition of the importance of muscle health in weight management.
• The company's previous clinical trials of enobosarm in muscle wasting conditions provide a strong rationale for its use in this context, differentiating it from other weight loss drugs.

Stakeholder Impact

• Shareholders may view the full enrollment of the clinical trial and improved financial results positively.
• Employees may be encouraged by the progress of the clinical trial and the company's financial stability.
• Customers may be interested in the potential of enobosarm as a treatment for obesity and muscle loss.
• Suppliers may benefit from the company's continued operations and development activities.
• Creditors may be reassured by the company's improved cash position.

Next Steps

• The company will continue the Phase 2b QUALITY clinical trial.
• Topline data from the Phase 2b QUALITY clinical trial is expected in January 2025.
• The company will continue the Phase 2b extension clinical trial.
• Topline results from the Phase 2b extension clinical study are expected in the second calendar quarter of 2025.

Key Dates

Keywords

enobosarm, obesity, clinical trial, muscle preservation, weight loss, GLP-1 receptor agonist, sarcopenic obesity, financial results, biopharmaceutical, Phase 2b, VERU